Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-10-05
2009-06-16
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S014800, C514S015800, C514S016700, C514S017400, C514S018700, C530S326000, C530S327000, C530S328000, C530S329000, C530S330000
Reexamination Certificate
active
07547676
ABSTRACT:
It has been demonstrated that one of Vitamin D Binding Protein (DBP) biological functions is to enhance the chemotactic activity of C5aand C5ades Arg. The present invention has found that peptides having sequences that substantially correspond to a specific region in the N-terminal domain I of DBP can block the DBP enhancement of C5aor C5ades Arg chemotactic activity. Based in this discovery the present invention provides DBP antagonist peptides and the use thereof for the treatment C5aor C5ades Arg-mediated disorders.
REFERENCES:
patent: 5326749 (1994-07-01), Yamamoto
patent: 5808109 (1998-09-01), Sindelar et al.
Kurata et al. ‘Analysis of Peptide Residues Interacting With MHC Molecule or T Cell Receptor.’ J. of Immun. vol. 144, No. 12, pp. 4526-4535. Jun. 1990.
White, P. et al., “The Multifunctional Properties and Characteristics of Vitamin D-binding Protein”,TEM 11(8): 320-327 (2000).
Gomme, P. T. et al., “Therapeutic potential of vitamin D-binding protein”,Trends in Biotechnology 22(7): 340-345 (2004).
Hirschfeld, J., “Immune-Electrophoretic Demonstration Of Qualitative Differences In Human Sera And Their Relation To The Haptoglobins”,Acta Path. 47(2): 160-168 (1959).
Haddad, J. G. et al., “Identification of the Sterol- and Actin-Binding Domains of Plasma Vitamin D Binding Protein (Gc-Globulin)”,Biochemistry 31: 7174-7181 (1992).
Swamy, N. et al., “Roles of the Structure and Orientation of Ligands and Ligand Mimics inside the Ligand-Binding Pocket of the Vitamin D-Binding Protein”,Biochemistry 36: 7432-7436 (1997).
Verboven, C. et al., “A structural basis for the unique binding features of the human vitamin D-binding protein”,Nature Structural Biology 9(2): 131-136 (2002).
Swamy, N. et al., “Biochemical and preliminary crystallographic characterization of the vitamin D sterol- and actin-binding by human vitamin D-binding protein”,Archives of Biochemistry and Biophysics 402: 14-23 (2002).
Head, J. F. et al., “Crystal Structure of the Complex between Actin and Human Vitamin D-Binding Protein at 2.5 Å Resolution”,Biochemistry 41: 9015-9020 (2002).
Otterbein, L. R. et al., “Crystal structures of the vitamin D-binding protein and its complex with actin: Structural basis of the actin-scavenger system”,PNAS 99(12): 8003-8008 (2002).
Köhl, Jög, “Anaphylatoxins and infectious and non-infectious inflammatory dieases”,Molecular Immunology 38: 175-187 (2001).
Gerard, N. P. et al., “The chemotactic receptor for human C5a anaphylatoxin”,Nature 349: 614-617 (1991).
Kew, R. R. et al., “Gc-Globulin (Vitamin D-binding Protein) Enhances the Neutrophil Chemotactic Activity of C5a and C5a des Arg”,J . Clin. Invest. 82: 364-369 (1988).
Perez, H. D. et al., “Identification of the C5a des Arg Cochemotaxin”,J . Clin. Invest. 82: 360-363 (1988).
Petrini, M. et al., “1,25-dihydroxycholecalciferol inhibits the cochemotactic activity of Gc (vitamin D binding protein)”,J. Endocrinol. Invest. 14: 405-408 (1991).
Metcalf, J. P. et al., “GcGlobulin Functions as a Cochemotaxin in the Lower Respiratory Tract”,Am. Rev. Respir. Dis. 143: 844-849 (1991).
Binder, R. et al., “Neutrophil priming by cytokines and vitamin D binding protein (Gc-globulin): impact on C5a-mediated chemotaxis, degranulaton and respiratory burst”,Molecular Immunology 36: 885-892 (1999).
Zwahlen, R. D. et al., “Chemotactic Competence Of Neutrophils From Neonatal Calves”,Inflammation 14(1): 109-123 (1990).
Piquette, C. A. et al., “Human monocyte chemotaxis to complement-derived chemotaxins is enhanced by Gc-globulin”,J. Leukoc. Biol. 55: 349-354 (1994).
Senior, R. M. et al., “Human C5a And C5a Des Arg Exhibit Chemotactic Activity For Fibroblasts”,J. Immunol. 141: 3570-3574 (1988).
Trujillo, G. et al., “Platelet-Derived Thrombospondin-1 Is Necessary for the Vitamin D-Binding Protein (Gc-Globulin) to Function as a Chemotactic Cofactor for C5a1”,J. Immunol. 173: 4130-4136 (2004).
Swamy N. et al., “Bacterial Expression of Human Vitamin D-Binding Protein (Gc2) in Functional Form1,2”,Protein Expression and Purification 10: 115-122 (1997).
Merritt, J. E. et al., “Use of fluo-3 to measure cytosolic CA2+in platelets and neutrophils”,Biochem. J. 269: 513-519 (1990).
Kew, R. R. et al., “Binding of Gc globulin (vitamin D binding protein to C5a or C5a des Arg is not necessary for co-chemotactic activity”,Journal of Leukocyte Biology 58: 55-58 (1995).
Zigmond, S. H. et al., “Leukocyte Locomotion And Chemotaxis”,The Journal of Experimental Medicine 137: 387-410 (1973).
Kew, R. R. et al., “Co-Chemotactic Effect of Gc-Globulin (Vitamin D Binding Protein) for C5a”,The Journal of Immunology 155: 5369-5374 (1995).
Cooke, N. E., “Rat Vitamin D Binding Protein”,The Journal of Biological Chemistry, 261 (7): 3441-3450 (1986).
Yang, F. et al., “Mapping and Conservation of the Group-Specific Component Gene in Mouse”,Genomics 7: 509-516 (1990).
Osawa, M. et al., “Cloning And Sequence Analysis Of cDNA Encodign Rabbit Vitamin D-Binding Protein (GC Globulin)”,Biochemistry and Molecular Biology International34(5): 1003-1009 (1994).
He, X. M. et al., “Atomic structure and chemistry of human serum albumin”,Nature 358: 209-215 (1992).
Mizwicki, M. et al., “Two Key Proteins of the Vitamin D Endocrine System Come Into Crystal Clear Focus: Comparison of the X-ray Structures of the Nuclear Receptor for 1 α,25 (OH)2Vitamin D3, the Plasma Vitamin D Binding Protein, and Their Ligands”,Journal of Bone and Mineral Research 18(5): 795-806 (2003).
Di Martino, S. J. et al., “Initial Characterization of the Vitamin D Binding Protein (Gc-Globulin) Binding Site on the Neutrophil Plasma Membrane: Evidence for a Chondroitin Sulfate Proteoglycan1”,The Journal of Immunology 163: 2135-2142 (1999).
Nykjaer, A. et al., “An Endocytic Pathway Essential for Renal Uptake and Activation of the Steroid 25-(OH) Vitamin D3”,Cell 96: 507-515 (1999).
Nykjaer, A. et al., “Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D3”,PNAS 98(24): 13895-13900 (2001).
Kanda, S. et al., “Effects of Vitamin D3-Binding Protein-Derived Macrophage Activating Factor (GcMAF) on Angiogenesis”,Journal of the National Cancer Institute 94(17): 1311-1319 (2002).
Licht, P. et al., “Identification and Structural characterization of a novel member of the virtamin D binding protein family”,Comp. Biochem. Physiol. (2001), Abstract.
McVoy, L. A. et al., “CD44 and Annexin A2 Mediate the C5a Chemotactic Cofactor Function of the Vitamin D Binding Protein1”,The Journal of Immunology 175: 4754-4760 (2005).
Kew Richard R.
Zhang Jianhua
Gupta Anish
Scully , Scott, Murphy & Presser, P.C.
The Research Foundation of State University of New York
LandOfFree
Antagonist peptides to the C5A chemotactic function of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonist peptides to the C5A chemotactic function of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonist peptides to the C5A chemotactic function of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4090318